Japan’s Toyama To Begin Trials Of Tamiflu Substitute In Europe This Year
This article was originally published in PharmAsia News
Executive Summary
Toyama Chemical of Japan says it intends to begin trials in Europe later this year on an influenza drug to treat strains now resistant to Roche's Tamiflu (oseltamivir). Toyama already has trials under way in Japan and the United States, with the Japanese trials expected to be completed next year. The company seeks to step up development using cash it received from Fujifilm Holdings, which acquired it as a subsidiary. Toyama expects its flu drug to become its next core product. (Click here for more - a subscription may be required